THE COLOGUARD TEST VS FIT
The Cologuard® test demonstrated superior sensitivity vs FIT* in detecting colorectal cancer (CRC) and advanced precancerous polyps1,2
In a 2014, prospective, head-to-head, point-in-time, 90-site, pivotal study of 10,000 patients aged 50 to 84 years at average risk for CRC, published in The New England Journal of Medicine, the Cologuard test demonstrated1†:
FIT failed to detect 3 times more total CRC findings (stages I to IV)1
Better outcomes with the Cologuard test
Explore more data comparing noninvasive options.
The Cologuard test is the superior CRC screening option vs FIT1,2
The proprietary Cologuard sDNA technology can analyze and detect 11 distinct biomarkers that are used to identify CRC and precancerous polyps.1,2
The Cologuard test1,2
Detects 11 biomarkers
Detects altered DNA and hemoglobin
Detects biomarkers that are continuously shed into the stool
Consistent detection of both left- and right-sided cancers
FIT1,3
Detects 1 biomarker
Only detects hemoglobin in stool
Detects hemoglobin from polyps or lesions that bleed intermittently
Less effective detecting proximal cancers
Unlike the Cologuard test, FIT only detects hemoglobin in stool, increasing the chance of a false negative result due to intermittent bleeding.1,3
Ease of use
Explore how the Cologuard test may help address potential barriers to CRC screening
- OC FIT-CHEK, Polymedco, Inc.
- In the pivotal study, screening colonoscopy was the reference method.1
- Cologuard specificity: 87% overall specificity, excluding CRC and advanced adenomas, and including all nonadvanced adenomas, nonneoplastic findings, and negative results on colonoscopy. There was 90% specificity in participants with no lesions biopsied on colonoscopy.1